Clinical Trial Update: Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update of uprosertib combined with dabrafenib and trametinib in patients with stage IIIC-IV melanoma (cutaneous/metastatic/unresectable).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma
• Unresectable Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)
• Uprosertib (uprosertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-10-14